Pharmaceutical OTM specialist Pharmainnovation Co., Ltd. announced that it has signed a memorandum of understanding (MOU) for cooperation in the development and commercialization of natural-substance-based products with healthcare platform specialist Carelance Co., Ltd. and beauty and medical device manufacturer and distributor Daoncare Co., Ltd.

The agreement was concluded to jointly promote the development of natural-substance-based products by combining each company’s research capabilities and commercialization experience, and to strengthen the competitiveness of the healthcare industry.

This collaboration is significant in that it aims to jointly drive the development and market expansion of natural-substance-based healthcare products by integrating research results on natural complex-based RCM technology with Carelance’s healthcare platform and commercialization capabilities and Daoncare’s research and development and bio-technology capabilities.

The three companies plan to establish an integrated cooperation system that spans from functional material research to product planning, development, and commercialization through joint research, and based on this, to sequentially launch a variety of healthcare products.

In particular, leveraging this agreement, the companies plan to begin full-scale development of inflammation-care products by utilizing a natural complex RCM platform based on cytokine inhibition technology. The company is reported to be conducting multi-faceted experimental and verification processes to enhance product safety and application suitability, based on the technical strengths of the RCM platform, and is preparing for product launches on this basis.

Choi Jin-hyo, CEO of Carelance, said, “This agreement will serve as an opportunity to strengthen a platform-based commercialization linkage structure so that research achievements based on natural substances can be realized as products in the actual market,” adding, “We will build a collaborative model that connects planning, distribution, and customer touchpoints so that the results of joint research can be delivered quickly to consumers.”

Kim Won-young, CEO of Daoncare, said, “Based on the development and manufacturing capabilities accumulated in the medical device sector, Daoncare plans to expand in a direction that integrates and links the natural-substance-based products developed through this joint research with various devices,” and added, “We will also actively work to expand device-based solutions to enhance product usability and application experience.”

Jeong Jong-yoon, CEO of Pharmainnovation, said, “Based on the research and productization technologies accumulated around the natural complex cytokine-inhibition RCM platform, this collaboration will further elevate the technological completeness of natural-substance-based products,” adding, “In particular, we will advance development by conducting research and verification in parallel to strengthen safety and application suitability, so that the products can earn trust in the market.”

Pharmainnovation is a pharmaceutical specialist company established in November last year by Dr. Jeong Jong-yoon, a former researcher at Kolmar Korea (now Genome Science), and is strengthening its integrated capabilities by introducing an OTM (One-Total Manufacturing) system that connects raw material development–planning–R&D–marketing–manufacturing in a one-stop process. Recently, the company has secured patented technology for an AI-based quality analysis-linked automated manufacturing system and completed construction of a new plant in Pyeongtaek.

Popular News